HERON THERAPEUTICS, INC. /DE/ Revenue Disclosure
The following provides disaggregated net product sales (in thousands):
|
|
For the Years Ended December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
CINVANTI net product sales |
|
$ |
96,758 |
|
|
$ |
100,079 |
|
|
$ |
94,869 |
|
ZYNRELEF net product sales |
|
|
38,072 |
|
|
|
25,546 |
|
|
|
17,727 |
|
APONVIE net product sales |
|
|
11,571 |
|
|
|
4,518 |
|
|
|
1,391 |
|
SUSTOL net product sales |
|
|
8,503 |
|
|
|
14,142 |
|
|
|
13,057 |
|
Total net product sales |
|
$ |
154,904 |
|
|
$ |
144,285 |
|
|
$ |
127,044 |
|
The following provides a summary of activity with respect to our product returns, distributor fees and discounts, rebates, administrative and other fees, which are included in other accrued liabilities on the consolidated balance sheets (in thousands):
|
|
|
|
|
|
|
|
Discounts, |
|
|
|
|
||||
|
|
|
|
|
|
|
|
Rebates, |
|
|
|
|
||||
|
|
Product |
|
|
Distributor |
|
|
Administrative and |
|
|
|
|
||||
|
|
Returns |
|
|
Fees |
|
|
Other Fees |
|
|
Total |
|
||||
Balance at December 31, 2024 |
|
$ |
3,791 |
|
|
$ |
5,883 |
|
|
$ |
27,745 |
|
|
$ |
37,419 |
|
Provision |
|
|
1,983 |
|
|
|
35,624 |
|
|
|
230,096 |
|
|
|
267,703 |
|
Payments/credits |
|
|
(1,259 |
) |
|
|
(34,179 |
) |
|
|
(223,689 |
) |
|
|
(259,127 |
) |
Balance at December 31, 2025 |
|
$ |
4,515 |
|
|
$ |
7,328 |
|
|
$ |
34,152 |
|
|
$ |
45,995 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 26, 2026 | Showing above |
| 2024 | Feb 27, 2025 | |
| 2023 | Mar 12, 2024 | |
| 2022 | Mar 29, 2023 | |
| 2021 | Feb 28, 2022 | |
About Revenue Disclosures
Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.
Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.